Search clinical trials for: Salmeterol/fluticasone 50/500 microgrammes

Total 771 results

Novartis Pharmaceuticals

Completed

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (FLASH)

COPD

India, South Africa, Egypt, Australia, Israel, Lebanon, Turkey, Philippines, Malaysia, Taiwan, Saudi Arabia
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline
Parexel

Completed

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

Asthma

United States, Australia, Poland, Russian Federation, Spain, Ukraine, Germany, Bulgaria, Argentina, Peru, South Africa, Taiwan, Belgium, Italy, Hungary, Korea, Republic of, Austria, Romania, Colombia, Slovakia, United Kingdom, Mexico and more
Anergis

Completed

Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy

Allergic Rhinitis | Rhinoconjunctivitis

France, Sweden, Lithuania, Denmark, Latvia, Poland, Switzerland
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

Asthma
Yungjin Pharm. Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

Korea, Republic of
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
GlaxoSmithKline

Completed

Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.

Asthma

United Kingdom, Belgium
Actavis Inc.

Withdrawn

Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Nemours Children's Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial (MICT)

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Leiden University Medical Center
GlaxoSmithKline; Academisch Ziekenhuis Groningen; Netherlands Organisation for... and other collaborators

Terminated

Modification Of Disease Outcome In COPD

Chronic Obstructive Pulmonary Disease

Netherlands
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Neutec Ar-Ge San ve Tic A.Ş

Terminated

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (COPD)

COPD

Turkey
AstraZeneca

Completed

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Spain, United Kingdom, New Zealand, Australia, Canada, Poland, Germany, Japan
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Asthma

Germany, Netherlands, United Kingdom, China, Romania, Bulgaria
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Best African American Response to Asthma Drugs (BARD)

Asthma

United States
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma

Germany
Assistance Publique - Hôpitaux de Paris

Completed

Ilomedin in Septic Shock With Persistent Microperfusion Defects (I-MICRO) (I-MICRO)

Septic Shock Hyperdynamic

France
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Roxane Laboratories
Vectura Limited

Completed

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Asthma

United States
GlaxoSmithKline

Completed

A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control

Asthma

Denmark, Switzerland
GlaxoSmithKline

Completed

Treatment Of Symptomatic Asthma In Children

Asthma

Netherlands
GlaxoSmithKline

Completed

Fall Epidemic Viral Pediatric Study

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
GlaxoSmithKline
Parexel

Completed

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI)

Asthma

United States, Australia, Spain, Taiwan, Bulgaria, Russian Federation, Ukraine, Argentina, Germany, Peru, Poland, South Africa, Thailand, Korea, Republic of, Austria, Belgium, Hungary, Italy, Slovakia, Malaysia, Czechia, Mexico, United... and more
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Bayer
Amgen

Completed

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma

United States
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan
Lawson Health Research Institute

Completed

Pleurodesis Using Hypertonic Glucose to Treat Post-operative Air Leaks (PLUG-I)

Postoperative Air Leak

Canada
West-Ward Pharmaceutical

Completed

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

Asthma

United States
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
GlaxoSmithKline

Completed

Safety, Blood Levels and Effects of GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece

3

Subscribe